Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 19, 2002
Localized unresectable neuroblastoma: results of treatment based on clinical prognostic factorsA Garaventa, L Boni, M S Lo Piccolo, et al.
Psychology & Health|April 27, 2023
Changes over time in self-efficacy to cope with cancer and well-being in women with breast cancer: a cross-cultural studyE C Karademas, I Roziner, P Simos, et al.
Breast Cancer Research and Treatment|September 15, 2020
Evaluation of endocrine therapy and patients preferences in early breast cancer: results of Elena studyE Montagna, E Pagan, V Bagnardi, et al.
Psychology & Health|February 11, 2022
The mutual determination of self-efficacy to cope with cancer and cancer-related coping over time: a prospective study in women with breast cancerE C Karademas, I Roziner, K Mazzocco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1997
MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 childrenG P Tonini, L Boni, A Pession, et al.
Journal of Clinical Psychology in Medical Settings|April 30, 2022
The Interplay Between Trait Resilience and Coping Self-efficacy in Patients with Breast Cancer: An International StudyE C Karademas, P Simos, R Pat-Horenczyk, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|December 12, 2023
CARDIOCARE: An integrated platform for the management of elderly multimorbid patients with breast cancer therapy induced cardiac toxicityG Karanasiou, L Koumakis, S Sfakianakis, et al.
British Journal of Cancer|October 31, 2014
Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplificationR Defferrari, K Mazzocco, I M Ambros, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2003
Quality assessment of genetic markers used for therapy stratificationI M Ambros, J Benard, M Boavida, et al.
British Journal of Cancer|December 8, 2011
Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study)G Schleiermacher, J Michon, A Ribeiro, et al.
Pageof 4